Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Acquisitions (2022 - 2023)

Zevra Therapeutics (ZVRA) has disclosed Acquisitions for 2 consecutive years, with $30.4 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Acquisitions changed N/A year-over-year to $30.4 million, compared with a TTM value of $44.5 million through Dec 2023, up 215.98%, and an annual FY2023 reading of $30.4 million, up 115.76% over the prior year.
  • Acquisitions was $30.4 million for Q4 2023 at Zevra Therapeutics, up from $14.1 million in the prior quarter.
  • Across five years, Acquisitions topped out at $30.4 million in Q4 2023 and bottomed at $14.1 million in Q3 2022.